BR0209254A - anticorpos de bloqueio cripto e usos dos mesmos - Google Patents

anticorpos de bloqueio cripto e usos dos mesmos

Info

Publication number
BR0209254A
BR0209254A BRPI0209254-9A BR0209254A BR0209254A BR 0209254 A BR0209254 A BR 0209254A BR 0209254 A BR0209254 A BR 0209254A BR 0209254 A BR0209254 A BR 0209254A
Authority
BR
Brazil
Prior art keywords
antibodies
crypto
bind
cripto
modulate
Prior art date
Application number
BRPI0209254-9A
Other languages
English (en)
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0209254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR0209254A publication Critical patent/BR0209254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTICORPOS DE BLOQUEIO CRIPTO E USOS DOS MESMOS". A invenção fornece anticorpos de bloqueio de Cripto, ou fragmentos biologicamente funcionais destes, e usos destes. Anticorpos que ligam Cripto e modulam a sinalização de Cripto são fornecidos. Anticorpos que ligam Cripto e bloqueiam a interação entre Cripto e ALK4 são fornecidos. Anticorpos que ligam Cripto e modulam o desenvolvimento de tumores também são fornecidos. Anticorpos que ligam Cripto, modulam a sinalização, e modulam o desenvolvimento de tumores também são fornecidos. Anticorpos que ligam Cripto, bloqueiam a interação entre Cripto e ALK4 e modulam o desenvolvimento de tumores são fornecidos. A invenção também fornece métodos para usar esses anticorpos em aplicações terapêuticas, diagnósticas, e de pesquisa.
BRPI0209254-9A 2001-04-26 2002-04-17 anticorpos de bloqueio cripto e usos dos mesmos BR0209254A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22
PCT/US2002/011950 WO2002088170A2 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR0209254A true BR0209254A (pt) 2006-10-03

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209254-9A BR0209254A (pt) 2001-04-26 2002-04-17 anticorpos de bloqueio cripto e usos dos mesmos

Country Status (34)

Country Link
US (6) US7531174B2 (pt)
EP (3) EP1974749B1 (pt)
JP (4) JP4307845B2 (pt)
KR (1) KR100592357B1 (pt)
CN (1) CN100352501C (pt)
AR (3) AR037223A1 (pt)
AT (2) ATE533508T1 (pt)
BG (1) BG108363A (pt)
BR (1) BR0209254A (pt)
CA (2) CA2443840C (pt)
CL (1) CL2009002199A1 (pt)
CY (1) CY1108960T1 (pt)
CZ (1) CZ20033208A3 (pt)
DE (1) DE60230868D1 (pt)
DK (1) DK1390389T3 (pt)
EA (1) EA007469B1 (pt)
EE (1) EE200300528A (pt)
ES (1) ES2321065T3 (pt)
GE (1) GEP20074091B (pt)
HK (1) HK1058935A1 (pt)
HU (1) HUP0501113A3 (pt)
IS (1) IS2662B (pt)
MX (1) MXPA03009797A (pt)
MY (2) MY150237A (pt)
NO (1) NO20034805L (pt)
NZ (1) NZ566268A (pt)
PL (1) PL207087B1 (pt)
PT (1) PT1390389E (pt)
RS (2) RS51635B (pt)
SG (1) SG157951A1 (pt)
SI (1) SI1390389T1 (pt)
SK (1) SK14432003A3 (pt)
TR (1) TR200301846T2 (pt)
WO (1) WO2002088170A2 (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AU2002334799B2 (en) * 2001-04-26 2009-05-07 Biogen Ma Inc. Cripto-specific antibodies
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
JP5033420B2 (ja) * 2003-09-15 2012-09-26 リサーチ ディベロップメント ファウンデーション アクチビン及びＴＧＦ−ｂのシグナリングのＣｒｉｐｔｏによる拮抗方法
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
EP1838736B1 (en) * 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2008014426A2 (en) * 2006-07-28 2008-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
CA2719385A1 (en) * 2008-04-21 2009-10-29 Merck Sharp & Dohme Corp. Pancreatic beta-cell mass biomarker
WO2010054328A2 (en) * 2008-11-07 2010-05-14 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
WO2012143499A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
SI2906251T1 (en) 2012-10-12 2018-01-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
KR101986404B1 (ko) 2012-10-12 2019-06-07 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EP2935268B2 (en) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
BR112016013861A2 (pt) 2013-12-16 2017-10-10 Genentech Inc conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
WO2015096982A1 (de) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CA2980611A1 (en) * 2015-04-07 2016-10-13 Paranta Biosciences Limited A method of treating neoplasias
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CN108025084B (zh) 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3047683C (en) 2017-02-08 2020-03-10 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (lt) 2017-04-18 2022-10-10 Medimmune Limited Pirolobenzodiazepino konjugatai
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
LT3668874T (lt) 2017-08-18 2022-03-25 Medimmune Limited Pirolobenzodiazepino konjugatai
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3801632A1 (en) 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
CN113271981A (zh) 2018-12-13 2021-08-17 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
ATE403001T1 (de) * 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
CA2370760A1 (en) * 1999-04-20 2000-10-26 William J. Kokolus Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
IL149116A0 (en) 1999-10-29 2002-11-10 Genentech Inc Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
EP1992644A1 (en) 2000-03-03 2008-11-19 Kyowa Hakko Kogyo Co., Ltd Antibodies against CCR4 and its fragments
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
CA2422814A1 (en) * 2000-09-18 2002-03-21 Biogen, Inc. Cripto mutant and uses thereof
WO2002059620A2 (en) 2001-01-26 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and quantification of cripto-1
JP2005503109A (ja) 2001-01-29 2005-02-03 アイデック ファーマスーティカルズ コーポレイション 修飾抗体と使用方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
AU2002334799B2 (en) * 2001-04-26 2009-05-07 Biogen Ma Inc. Cripto-specific antibodies
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
AU2002330015B2 (en) * 2001-09-18 2008-02-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040014690A1 (en) * 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
JP5033420B2 (ja) * 2003-09-15 2012-09-26 リサーチ ディベロップメント ファウンデーション アクチビン及びＴＧＦ−ｂのシグナリングのＣｒｉｐｔｏによる拮抗方法
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
EP2021510A2 (en) 2006-04-28 2009-02-11 Biogen Idec MA Inc. Composition and methods for the detection of cripto-3

Also Published As

Publication number Publication date
CN100352501C (zh) 2007-12-05
HUP0501113A3 (en) 2007-12-28
PT1390389E (pt) 2009-04-03
JP2004534020A (ja) 2004-11-11
SI1390389T1 (sl) 2009-06-30
BG108363A (bg) 2004-09-30
EP1974749A1 (en) 2008-10-01
HK1058935A1 (en) 2004-06-11
JP2009108100A (ja) 2009-05-21
CZ20033208A3 (en) 2004-03-17
US7674462B2 (en) 2010-03-09
EP1390389A4 (en) 2004-09-22
NZ566268A (en) 2009-09-25
CN1606453A (zh) 2005-04-13
RS51635B (sr) 2011-08-31
US20090285818A1 (en) 2009-11-19
EA200301158A1 (ru) 2005-06-30
US8003763B2 (en) 2011-08-23
US7888052B2 (en) 2011-02-15
SG157951A1 (en) 2010-01-29
JP2010163438A (ja) 2010-07-29
GEP20074091B (en) 2007-04-25
DK1390389T3 (da) 2009-04-20
CL2009002199A1 (es) 2010-05-07
EP1390389A2 (en) 2004-02-25
NO20034805D0 (no) 2003-10-27
HUP0501113A2 (en) 2007-05-02
KR20040028744A (ko) 2004-04-03
JP4575983B2 (ja) 2010-11-04
PL373513A1 (en) 2005-09-05
ES2321065T3 (es) 2009-06-02
US7531174B2 (en) 2009-05-12
US8673303B2 (en) 2014-03-18
MY150237A (en) 2013-12-31
EP1974749B1 (en) 2011-11-16
DE60230868D1 (de) 2009-03-05
EA007469B1 (ru) 2006-10-27
EP1390389B1 (en) 2009-01-14
JP2005314436A (ja) 2005-11-10
CA2715570A1 (en) 2002-11-07
IS2662B (is) 2010-08-15
EE200300528A (et) 2004-08-16
AR072554A2 (es) 2010-09-08
US20040146940A1 (en) 2004-07-29
JP4307845B2 (ja) 2009-08-05
US20100202962A1 (en) 2010-08-12
ATE420659T1 (de) 2009-01-15
TR200301846T2 (tr) 2006-10-26
US20080166341A1 (en) 2008-07-10
CA2443840A1 (en) 2002-11-07
US20090286265A1 (en) 2009-11-19
WO2002088170A2 (en) 2002-11-07
YU84903A (sh) 2006-05-25
MXPA03009797A (es) 2004-01-29
EP2316486A3 (en) 2011-09-07
KR100592357B1 (ko) 2006-06-22
AR037223A1 (es) 2004-11-03
AR077759A2 (es) 2011-09-21
IS6999A (is) 2003-10-24
RS20110024A (en) 2011-08-31
CY1108960T1 (el) 2014-07-02
EP2316486A2 (en) 2011-05-04
SK14432003A3 (sk) 2004-07-07
NO20034805L (no) 2003-12-23
CA2443840C (en) 2010-10-26
ATE533508T1 (de) 2011-12-15
PL207087B1 (pl) 2010-10-29
MY157382A (en) 2016-06-15
WO2002088170A3 (en) 2003-12-24
US20120195912A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE60032486D1 (de) Prion protein peptide und deren verwendung
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
ATE215084T1 (de) Imidazopyridin-azolidinone
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
ATE490981T1 (de) Criptospezifische antikörper
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2232 DE 15/10/2013.